Global biopharmaceutical company Bionomics
(ASX:BNO) today announced they will host Key Opinion Leader meetings focused on the treatment of post traumatic stress disorder.
The meetings will take place in London and New York later this month.
Bionomics lead drug candidate is BNC210 – it’s currently in phase 2 for the treatment of generalised anxiety disorder and for post-traumatic stress disorder.
The meetings will give an insight into the pipeline progress into their work regarding PTSD and how they hope to help sufferers.
An estimated almost 4 per cent of American men suffer from PTSD.
Shares in Bionomics
(ASX:BNO) 0.91 per cent lower at $0.55.
